POPULARITY
4 episodes with Pathologic
5 episodes with Pathologic
3 episodes with Pathologic
5 episodes with Pathologic
2 episodes with Pathologic
5 episodes with Pathologic
4 episodes with Pathologic
3 episodes with Pathologic
5 episodes with Pathologic
4 episodes with Pathologic
6 episodes with Pathologic
3 episodes with Pathologic
4 episodes with Pathologic
3 episodes with Pathologic
5 episodes with Pathologic
2 episodes with Pathologic
3 episodes with Pathologic
4 episodes with Pathologic
Welcome to another exciting episode of PICU Doc on Call! Today, we're diving deep into the world of pediatric critical care with our expert hosts, Dr. Rahul Damania, Dr. Pradip Kamat, and Dr. Monica Gray. Get ready to unravel the mysteries of the oxygen extraction ratio (O2ER) and its pivotal role in managing pediatric acute respiratory distress syndrome (ARDS) and multi-organ dysfunction.Picture this: a seven-year-old girl battling severe pneumonia that spirals into ARDS and septic shock. Our hosts walk you through this gripping case, shedding light on calculating O2ER and why central venous oxygen saturation (ScvO2) is a game-changer. They'll share their top strategies for optimizing oxygen delivery and cutting down on oxygen demand.But that's not all! This episode is all about the holistic approach to managing critically ill pediatric patients. Tune in to discover how these insights can lead to better outcomes for our youngest and most vulnerable patients. Don't miss out on this vital conversation!Show Highlights:Clinical significance of the oxygen extraction ratio (O2ER) in pediatric critical careImportance of understanding oxygen delivery and consumption in critically ill patientsCalculation and interpretation of O2ER and its relationship to central venous oxygen saturation (ScvO2)Physiological concepts related to oxygenation, including intrapulmonary shunting and ventilation-perfusion mismatchManagement strategies for increasing oxygen delivery and reducing oxygen demand in ARDS and septic shockInterventions such as blood transfusions, sedation, and optimization of cardiac outputImplications of lactic acidosis and anaerobic metabolism in the context of inadequate oxygen deliveryHolistic approach to patient management, focusing on both numerical values and overall metabolic needsWe welcome you to share your feedback, subscribe & place a review on our podcast! Please visit our website picudoconcall.org.References:Fuhrman B.P. & Zimmerman J.J. (Eds.). Pediatric Critical Care, 6th ed. Elsevier; 2021. (Key concepts of oxygen delivery, consumption, and extraction in shock states are discussed in Chapter 13) .Nichols D.G. (Ed.). Roger's Textbook of Pediatric Intensive Care, 5th ed. Wolters Kluwer; 2016. (Comprehensive review of oxygen transport and utilization in critically ill children, including ARDS and shock).Lucking S.E., Williams T.M., Chaten F.C., et al. Dependence of oxygen consumption on oxygen delivery in children with hyperdynamic septic shock and low oxygen extraction. Crit Care Med. 1990;18(12):1316–1319. doi:10.1097/00003246-199012000-00002.Ronco J.J., Fenwick J.C., Tweeddale M.G., et al. Pathologic dependence of oxygen consumption on oxygen delivery in acute respiratory failure. Chest. 1990;98(6):1463–1466. doi:10.1378/chest.98.6.1463 .Carcillo J.A., Davis A.L., Zaritsky A. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med. 2002;30(6):1365–1378. (ACCM guidelines emphasizing ScvO₂ targets in shock) .Emeriaud G, López-Fernández YM, Iyer NP, et al; PALICC-2 Group; PALISI Network. Executive summary of the second international guidelines for the diagnosis and management of pediatric ARDS (PALICC-2). Pediatr Crit Care Med. 2023;24(2):143–168. doi:10.1097/PCC.0000000000003147.
Soltaram o prólogo de Videogame 3, e eu mal posso esperar pra sair tudo.Mandem e-mails com comentários para: umeventualocultismo@gmail.comEntrevista com a Alphyna: https://youtu.be/VSYLYJhZriYParticipantes: Pedro Santos e Vítor BatistaMúsicas: Main Theme (Pathologic 3: Quarantine OST)
The distant troglodyte descendants of Jamie and Marsh relive memories of the before-times and the joyous videogames that were once played, namely: 1000xResist, Type Help and Pathologic 3: Quarantine. Pathologic 3: Quarantine is the demo for a larger forthcoming game, and is harrowing in about every way it can be. 1000xResist is a brilliant game [...]
Ruské studio Ice-Pick Lodge se už dvě dekády specializuje na hry, které nechtějí být jen hrami. Jejich díla jsou experimenty, filozofickými úvahami a často i psychologickými testy odolnosti. Teď přichází z demem svého nejnovějšího počinu Pathologic 3 – třetí pokus o zpracování téhož konceptu. Má smysl se do něj opět ponořit?
Ruské studio Ice-Pick Lodge se už dvě dekády specializuje na hry, které nechtějí být jen hrami. Jejich díla jsou experimenty, filozofickými úvahami a často i psychologickými testy odolnosti. Teď přichází z demem svého nejnovějšího počinu Pathologic 3 – třetí pokus o zpracování téhož konceptu. Má smysl se do něj opět ponořit?Všechny díly podcastu Quest můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.
This week Bob and Connor are joined by friend of the show and streamer extraordinaire Momiji! They talk Nubby's Number Factory, Resident Evil 4 Remake, Another Crab's Treasure, God of War Ragnarök, Pathologic 3: Quarantine, Caves of Qud, and more!!!Watch Momiji on TwitchFollow us on Instagram Leave us a voicemail at (804) 286-0626 and consider supporting us through our Patreon Check out the Discord! News Links:GDC Awards ResultsVideo Game Workers Launch Nationwide UnionNintendo Logo Will Now Be Featured on Seattle Mariner Jerseys
Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
This episode, Dalton and Willie chat about the new DOOM game, Willie has some stories from the Chess boards, and Dalton beat a few RPGs. Then, the boys dive into the bleak, depressing world of Pathologic 2. Did they save the town, or did the plague win? Tune in to find out! Come join our Discord and Vote on polls for games! bit.ly/TSMPDISCORD Patreon! https://www.patreon.com/thesteammachinepodcast Big Thanks to Our patrons who donate 10 dollars or more! Nate “Sir Cogsworth the 7th of June-iper” Jeff “The Original Expendable, Mr. Syllables Ole Jeffy Lube ”Aries or Adam “Ariesoradam” Shoutout to his podcast Revival and Extinction James “The Steam Machine Hall Monitor” Hall Team Retrogue Check Him out on Youtube “Mr. Puzzles” Dane Himself Chad "The Mad Lad NO C IN" Shaffer Flyin' Brian Doran Grey The RPG Wolverine Logan Joreid Biltzy the Dragon LINK TO WEBSITE! https://bit.ly/TheSteamMachinePodcast Shoutout to YABSPOD(Yet Another BS Podcast) Shoutout to JRPG Report Shoutout to Revival and Extinction Shoutout to TeamRetrogue Shoutout to Dane and Jeff's Media Dump Merch Link! https://tsmpproductions.threadless.com Bandcamp link for Nile the Nightmare- https://nilethenightmare.bandcamp.com/ DALTON'S NEW ALBUMS Hip-hop -https://nilethenightmare.bandcamp.com/album/the-love-and-hate-mixtape Electronic - https://nilethenightmare.bandcamp.com/album/vivid-dream-world
I once heard the original Pathologic (Ice-Pick Lodge) described as "the best game you shouldn't play", which is an oddly appealing pitch to me. I need to see what it is that puts it in that category, ya know? Luckily for me, Pathologic 2 exists and seems to be the preferred way for many to get the Pathologic experience, and I was not disappointed with what I got. Dense worldbuilding, intriguing and mysterious characters, harsh but meaningful survival systems and more await anyone who decides to take our recommendation and play Pathologic 2. Guest info: Jack, or as you may know him online, Piboi. TIMESTAMPS * Allegations against Nikolay Dybowski 0:00 * Intros/Personal Histories/Opening Thoughts 2:14 * Story Setup 15:18 * Presentation 38:26 * Gameplay 55:01 * Gameplay, continued 1:19:11 * SPOILER WALL 1:36:41 Music used in the episode: * Shaman from the Downtown (Theodor Bastard) * Darkness (Theodor Bastard) * Disappearing (Theodor Bastard) * Archaic Way (Vasily Kashnikov) * Eternal Sacrifice (Vasily Kashnikov, Nick Balinov) * Miracle Workshop (Vasily Kashnikov) * Window to the Past (Vasily Kashnikov) * Steppe (Vasily Kashnikov) Support Tales from the Backlog on Patreon! (https://patreon.com/realdavejackson) or buy me a coffee on Ko-fi (https://ko-fi.com/realdavejackson)! Join the Tales from the Backlog Discord server! (https://discord.gg/V3ZHz3vYQR) Social Media: Instagram (https://www.instagram.com/talesfromthebacklog/) Twitter (https://twitter.com/tftblpod) Facebook (https://www.facebook.com/TalesfromtheBacklog/) Cover art by Jack Allen- find him at https://www.instagram.com/jackallencaricatures/ and his other pages (https://linktr.ee/JackAllenCaricatures) Listen to A Top 3 Podcast on Apple (https://podcasts.apple.com/us/podcast/a-top-3-podcast/id1555269504), Spotify (https://open.spotify.com/show/2euGp3pWi7Hy1c6fmY526O?si=0ebcb770618c460c) and other podcast platforms (atop3podcast.fireside.fm)!
cw: suicide, death, the plague Grace and Rose enter the plagued town and explore its thematic shades of death and life, roles and personhood, ease and difficulty that permiate its walls and earth. Find some bread and meat and sit down with us!
I wanted to get a Handheld Talk episode out for the holiday but unfortunately, due to my own carelessness, my files for that have been lost. Instead, enjoy this little playlist I threw together featuring songs from games we played this year. Hope you enjoy! See you soon for our Pathologic 2 episode. —RosePlaylist:"Two of Everything" by Tori Beaumont from "Immortality""Kusabi Love or Die Remix" by Masafumi Takada from "The Silver Case""Clair de Lune" by Claude Debussy, arranged by Masafumi Takada from "The Evil Within 2""Fear II" by Yutaka Minobe from “Rule of Rose”"Koe" by Tsukiko Amano from “Fatal Frame III: The Tormented”"Miracle Workshop" by Vasily Kashnikov from “Pathologic 2”"You Came Back" by Ockeroid from “Crow Country”"Dead Space” by Jason Graves from “Dead Space”"Silencio Zero" by Vasily Kashnikov from “Pathologic 2”"The Tormented" by Tsukiko Amano and Ayako Toyoda from “Fatal Frame III: The Tormented”"The Reverse Will (Unseen Paths)" by Akria Yamaoka from “Silent Hill 2 (2024)”"Opening" by Nainita Desai from “Immortality”"Fairtale Town" by Ockeroid from “Crow Country””Shoot Speed" by Masafumi Takada from “Killer7”"Twyrine" by Vasily Kashnikov from “Pathologic 2”"Backbiting" by Yutaka Minobe from “Rule of Rose”"The Attic" Yutaka Minobe from “Rule of Rose”"Rave On" Masafumi Takada from “Killer7”
Side Quests is back and so is host Dave Jackson! He is a podcaster and surgeon, also known as the Haruspex! The game he is talking about today is Pathologic 2 by Ice-Pick Lodge and tinyBuild. You can also listen to his podcasts, A Top 3 Podcast and Tales from the Backlog! We have a Patreon! Gain access to episode shout outs, bonus content, early downloads of regular episodes, an exclusive rss feed and more! Click here! You can find the show on Bluesky, Instagram and YouTube! Please rate and review us on Apple Podcasts! Rate us on Spotify! Wanna join the Certain POV Discord? Click here!
Episode #346 of BGMania: A Video Game Music Podcast. This week on the show, Bryan and Bedroth from RPGera do their best to not catch the black death while exploring games and music all about the Plague! Email the show at bgmaniapodcast@gmail.com with requests for upcoming episodes, questions, feedback, comments, concerns, or whatever you want! Special thanks to our Executive Producers: Jexak, Xancu, & Jeff. EPISODE PLAYLIST AND CREDITS Slay the Darkness from Vigil: The Longest Night [Jouni Valjakka, 2020] Witness the Sickness from Deathbulge: Battle of the Bands [Leslie Wai, 2023] Drown with the Sickness -Stage 3 Boss- from Turrican: Rise of the Machine [Chris Huelsbeck, 2018] Village of the Damned from Shovel Knight: Plague of Shadows [Arcubalis, 2015] Plague Awake Here from Pathologic 2 [Vasily 'Mushroomer' Kashnikov, 2019] The Plagued Forest -Venom- from Tevi [3R2, Oli Jan, Triodust, Bo-Xun Lin & Brandon Yates, 2023] The Plague's Song from Figment [Stöj Snak, 2017] Vat of the Plague Fiend from Gauntlet: Dark Legacy [John Paul & Barry Leitch, 2000] Come Out and Plague from Horace [Paul Helman, 2019] Pestilence's Lab from Peace, Death! 2 [Anton Brezhnev, 2021] Plague Wing from Hearthstone: Curse of Naxxramas [Peter McConnell, 2014] Plagued Nemesis from Bleak Faith: Forsaken [Martel, 2023] Ô ma belle lune from A Plague Tale: Requiem [Olivier Deriviere feat. Estonian Philharmonic Chamber Choir, 2022] Plague's Nest from Fenix Rage [José Mora, 2014] SUPPORT US Patreon: https://patreon.com/rpgera CONTACT US Website: https://rpgera.com Discord: https://discord.gg/cC73Heu Twitch: https://twitch.tv/therpgera Twitter: https://twitter.com/OriginalLDG Instagram: https://instagram.com/bryan.ldg/ Facebook: https://facebook.com/leveldowngaming RPGERA PODCAST NETWORK Very Good Music: A VGM Podcast The Movie Bar
Hey Leute,ich bin im Urlaub und deswegen gibt es heute nur eine kurze Episode.Trotzdem viel Spaß!PatreonSteadyHolt euch wie immer Getränke bei HOLY mit meinem Code "SPECKOBST5" für einen 5€-Rabatt bei einer Erstbestellung oder spart 10% mit dem Code "SPECKOBST"Timestamps00:00 Keine Spiel?NEUE SPIELE06:21 Until Dawn RemakeNEWS12:45 PS5 Ads waren ein Bug?15:29 Deutschland macht Stress auf Steam19:12 Assassin's Creed Mirage erscheint auf Steam20:05 343 Studios benennt sich in Halo Studios um22:30 Alien Isolation erhält ein Sequel24:41 Pathologic 3 angekündigt28:15 Bakeru bekommt eine physische Version im Westen28:59 Red Dead Redemption kommt für PCTHEMA30:15 Wie schreibt man eine gute Review?FRAGEN43:28 Welche Videospiele Genres magst du und welche nicht?45:46 Was hältst du von Furukawas Führungsstil?48:03 Bist du Team Wireless Controller oder sind dir Controller mit Kabel lieber?50:11 Findest du, dass Game Overs und Leben veraltet sind?
Kole, Dennis, and Jala talk about the Silent Hill 2 Remake, Diablo IV: Vessel of Hatred, Mouthwashing, and much more! The Grind: Jala: Shining Force III. Shining in the Darkness. Lid Astray. King of Fighters 14 and 15. Kole: Silent Hill 2 Remake. Mouthwashing. Dennis: We < 3 Katamari REROLL. Control. Diablo IV: Vessel of Hatred. The Multiplayer: What was the best year for video games? The End Boss: Alien Isolation is getting a sequel. Pathologic 3 will be the Bachelor, Daniil Dankovsky's story. Pinball Spire is a pinball Metroidvania.
Bienvenidas y bienvenidos a Recarga Activa, el podcast diario de AnaitGames en el que filtramos lo más relevante de la actualidad del videojuego en pildorazos de 15 minutos: Alien Isolation celebra su décimo aniversario anunciado su secuela. Con el director del original Pathologic 3 se publicará en 2025 El port original para PC de Horizon Zero Dawn es retirado de Steam Detroit Become Human supera los 10 millones de ventas Suscríbete para recibir el siguiente episodio en tu gestor de podcasts favorito. Puedes apoyar nuestro proyecto (y acceder a un montón de contenido exclusivo) en Patreon: https://www.patreon.com/anaitreload ♫ Sintonía del programa: Senseless, de Johny Grimes Learn more about your ad choices. Visit megaphone.fm/adchoices
Neste episódio sobre o clássico cult Pathologic 2, recebemos novamente Gabriel Bichir, autor do ensaio e Doutorando em Filosofia pela Faculdade de Filosofia, Letras e Ciências Humanas da Universidade de São Paulo (FFLCH) com a tese História e Natureza em Hegel. Leia o ensaio completo Pathologic 2: o teatro como peste. Citado no episódio: Bloodborne is a total Hypocrite, do canal SweetIsOnline. Ouça também as outras duas participações de Gabriel no Regras do Jogo: Regras do Jogo #165 – Um novo niilismo: extrema direita e aceleracionismo Regras do Jogo #123 – Life is Strange: Nostalgia como utopia Ajude a financiar o Holodeck Design no Apoia.se e Orelo.cc ou fazendo doações pelo PicPay. Siga o Holodeck Design no Twitter, Facebook, Instagram e TikTok e entre no grupo para ouvintes do Telegram! Nossos episódios são gravados ao vivo em nosso canal na Twitch e YouTube, faça parte também da conversa. Participantes Fernando Henrique Anderson do Patrocínio Gabriel Bichir Cupons de Desconto regrasdojogo – 10% Descontos em todas as camisas da Veste Esquerda. Músicas: Persona 5 – Beneath The Mask lofi chill remix Modest by default - 我只需要看花
One of the long-standing assumptions in Sports Medicine is that anterosuperior labral variants including the Buford Complex and Sublabral Foramen are non-pathologic, normal anatomic variants of the shoulder joint. But is this true? Dr. Eric Edmonds from Rady Children's Hospital in San Diego challenges this assumption and our accepted practice of ignoring these findings when observed arthroscopically.
Aleks' uses scissors to solve a workplace dispute, a mysterious new character emerges in the 3DS sidequest, Tad and Joe make it out of Chicago and Tad becomes a lawyer again!Imgur Album: https://imgur.com/a/lmtya-noyz-boyz-40-EZjkw3lTalking Points: Fake-o THACO,Zanzibarts Nephew,Aleks Art Update,Megaman,KING ME,Mascot Culture,Aleks so-called-friends,Italian Director Babagucci Babagucci,Pathologic,Cool Horse Pics,Fallout London 500 ciggies,the VR chat knights,the VR toybox,he doesn't get it chat,everything you want to be,LARP,Walmart VR training,"I saw diogenes in the corner [...] and told him to stop",Walmart VR Ed,shadowboxing in the walmart VR training,reverse sasquatch,Bill's having trouble with a customer,my spaces were liminal,putting my hands in the beans,walmart VR speedrun tech,Main quest,side quest,3ds streetpass,my pink puzzlepiece,the infamous foot call,vendor trash,magic mike,adventure with a younger person,the hustler kid,4freee,roblox,robux,free robux 2024,free roblox 2023,now how to get free robux etc.,banana game,disposable videos,throwing shade on hot-tubers,drama youtubers,Channel 5,Joe's street advice,stucked in traffic,Igor's Dungeon,Miitopia Cobes,mukbang cartoon man,midside out 2,2013 Impala,Lawyer Tad returns and Tad's main quest has begun! Check out the website for links to our shows on iTunes, GooglePlay and Spotify► http://www.lmtya.com► https://spoti.fi/2Q55yfLPeep us on Twitter► @LetMeTellYouPDOfficial Discord► https://discord.gg/SqyXJ9R/////// SHILL CORNER ///////► https://www.patreon.com/LMTYALMTYA shirts!► https://lmtya.myspreadshop.com/all/////// SHILL CORNER ///////
There are multiple team members who all play an important role in providing coordinated multidisciplinary care for the betterment of patients with sarcomas and tumors. A pathologist is a key member of the team with an extremely important role. Pathologic analysis remains the standard for diagnosis and tumor analysis. We discuss the role of the pathologist in tumor diagnosis with Dr. Obeidin Farres. Obeidin F. What's new in bone and soft tissue pathology 2023: guidelines for molecular testing. J Pathol Transl Med. 2023 May;57(3):184-187. Find out More about our Doctors: Dr. Izuchukwu Ibe: www.linkedin.com/in/izuchukwu-ibe-a073537a/ Dr. Elyse Brinkmann: www.linkedin.com/in/elyse-brinkmann/
Dr. John Sweetenham shares highlights from Day 2 of the 2024 ASCO Annual Meeting, including potentially practice-changing results in advanced Hodgkin lymphoma, intriguing data on the effect of metformin on active surveillance for prostate cancer, and the potential of AI to improve patient outreach and adherence to medical appointments. TRANSCRIPT Dr. John Sweetenham: I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my top takeaways on selected abstracts from Day 2 of the 2024 ASCO Annual Meeting. Today's selection features potentially practice-changing results for patients with advanced stage Hodgkin lymphoma, results from a large trial testing the effects of metformin in patients on active surveillance for their prostate cancer, and early results giving insights into the benefits that artificial intelligence may bring to address disparities in cancer care. My full disclosures are available in the transcript of this episode. The first of today's abstracts is LBA7000, which reports the results from a large international randomized trial in patients with advanced Hodgkin lymphoma, presented by Dr. Peter Borchmann from the German Hodgkin Study Group. Since Hodgkin lymphoma typically affects adults in their 20s and 30s, the focus of clinical trials in recent years has been on achieving high rates of disease control while at the same time reducing the potential for short-term and long-term toxicities associated with classical chemotherapy and radiation therapy regimens. Particular emphasis has been given to reducing risk for secondary malignancy and impaired reproductive function in long-term survivors. Building on the back of previous studies from this group, the escalated BEACOPP regimen was modified to reduce the overall duration of treatment and the potential for toxicity by incorporating novel agents, including brentuximab vedotin. This novel regimen, known as BrECADD, was compared with escalated BEACOPP in a randomized trial, HD21. Patients received 4 or 6 cycles of therapy based on the response of their disease to the first 2 cycles assessed by interim PET scan. 1,482 patients were randomized, 740 to escalated BEACOPP and 742 to BrECADD, with median follow-up at 48 months. The 4-year progression-free survival was 94.3% with BrECADD, compared with 90.9% for escalated BEACOPP, with a hazard ratio of 0.66. These results are particularly noteworthy since 64% of patients on the BrECADD arm had a negative PET scan after 2 cycles of therapy and therefore received a total of just 4 cycles, reducing their risk of toxicity. On that note, lower rates of treatment related toxicity were observed with BrECADD. Specifically, hematologic toxicity and peripheral sensory neuropathy were less frequently seen. Female reproductive toxicity was lower with BrECADD, with more than 95% of women having normal FSH levels after 1 year on BrECADD, compared with 73% on escalated BEACOPP. Dr. Borchmann also noted that recovery of male reproductive function was improved with BrECADD, although details were not provided. These are impressive data, although no overall survival difference was observed. This is not surprising in view of the effective salvage therapies available to patients whose disease relapses after first-line therapy. The authors conclude that these results are unprecedented for the first-line treatment of Hodgkin lymphoma and that the BrECADD regimen should be considered as a new standard of care option. Although these results are likely to change practice in some parts of the world, particularly in Europe, it's less clear whether they will impact current treatments in the United States, where modifications to the ABVD regimen, including the addition of brentuximab vedotin and more recently nivolumab, have been the subject of recent randomized trials. That said, these data add to the increasing evidence that cure of advanced Hodgkin lymphoma is possible in most patients, and that concerns over short- and long-term toxicities of therapy for this young group of patients are being addressed using several strategies. The next abstract, LBA5002 reports the results of a Canadian study investigating the use of metformin to slow or prevent progression in patients with low-risk prostate cancer on active surveillance. Professor Anthony Joshua pointed out in his presentation that there are extensive epidemiologic, biologic, and clinical data suggesting that metformin may affect the progression of low-risk prostate cancer, but this has not previously been evaluated in the context of a randomized controlled trial. The MAST study – or Metformin Active Surveillance Trial – was designed to prospectively evaluate the use of metformin in patients with low-risk prostate cancer eligible for active surveillance. Patients were eligible for the trial if they had been diagnosed within the previous 12 months, had low-risk prostate cancer, defined as a Gleason score of less than 6 in less than one-third of cores involved and less than 50% of any 1 core plus having a PSA of less than 10. These patients were randomized to either active surveillance plus placebo or active surveillance plus metformin at an initial dose of 850 milligrams daily for 1 month, followed by 850 milligrams twice daily for 35 months. Evaluations including prostate biopsies were performed at baseline, then at 18 and 36 months. 405 patients were randomized 1:1 and were well matched for patient characteristics and risk factors. Pathologic and therapeutic progression were the major endpoints of the study. The overall results of the study showed that the use of metformin in this population had no effect on pathologic or treatment progression. Although not a planned analysis, there was a signal that the use of metformin may accelerate progression in certain patients, including those with a high BMI. This study shows definitively that metformin should not be used in low-risk, localized prostate cancer patients who are eligible for active surveillance. There are many unanswered questions about its use in other situations in prostate cancer and in low-risk patients who also have diabetes. The final selection for today is Abstract 100. In this presentation, Dr. Alyson Moadel from Montefiore Einstein Comprehensive Cancer Centre in New York City described an artificial intelligence platform which showed potential to improve patient outreach and adherence to medical appointments. In underserved communities of color, barriers to colorectal cancer screening can contribute to disparities due to late-stage diagnosis and poor outcomes. Despite active outreach by skilled patient navigators at this center, which serves an ethnically minoritized and disadvantaged population, 59% of patients either canceled or did not show for their colonoscopy appointments in 2022. While patient navigator reengagement efforts led to 21% eventually completing colonoscopy, 1,500 patients did not undergo potentially lifesaving colon cancer screening that year. The study used MyEleanor, a virtual patient navigator that engages in personalized AI conversation, to target 2,400 patients who had not attended their colonoscopy appointment in 2022 to 2023. MyEleanor called patients to discuss rescheduling, assessed barriers to uptake, offered live transfers to clinical staff to reschedule, and provided procedure preparation reminder calls. During the study, 57% of patients engaged with MyEleanor, with 58% of this group or 33% overall accepting the live transfer. The rate of completed colonoscopies for patients who did not show for their initial appointment nearly doubled from 10% to 19% after the initiation of MyEleanor. Overall patient volume increased by 36%. Nearly one-third of the patients reported at least 2 barriers to screening. Top barriers included lack of perceived need, time, medical mistrust, concerns about findings, and cost. The investigators plan to extend these studies to explore the impact of this tool on patient preparation adherence, staff burden, and revenue. As data emerge on the potential applications of AI in the cancer care ecosystem, it's exciting to see how tools such as this have the potential to improve rates of prevention and early detection and address cancer care disparities. Join me again tomorrow to hear more top takeaways from ASCO24. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness
During the 2024 Society of Surgical Oncology Annual Meeting (SSO), CancerNetwork® spoke with a variety of surgical oncology experts regarding the topline data they presented. Each conversation also expanded upon how these results can be implemented into the clinical space and the next research steps. First, Adrienne Bruce Shannon, MD, a complex general surgical oncology fellow at Moffitt Cancer Center, discussed findings from her presentation highlighting responses to neoadjuvant immune checkpoint inhibitors among select patients with mismatch repair deficient (dMMR) gastroesophageal cancer.1 Looking ahead, Shannon described her aim to optimize treatment strategies for this patient population, which may include assessing whether single-agent treatment can be efficacious while avoiding toxicity associated with combination regimens. Next, Sean Dineen, MD, an associate member in the Gastrointestinal Department, section leader for Peritoneal Disease, and the program director for the Complex General Surgical Oncology Fellowship at Moffitt Cancer Center, spoke about his session, which was aimed at determining appropriate conditions for using cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) for those with colorectal cancer (CRC) and peritoneal metastases.2 Dineen highlighted that there is “good evidence” in support of HIPEC as a “valid treatment option” and emphasized the need to encourage medical oncologists to refer patients for consideration of surgery. Additionally, he spoke about other advancements he hopes to see in this patient population, including the development of markers of various disease volumes that can help identify potential recurrence in those who receive surgery. Finally, Muhammad Talha Waheed, MD, a research fellow in the Department of Surgical Oncology at City of Hope National Medical Center in Duarte, California, detailed findings from a retrospective analysis indicating disparate treatment access and cancer-related mortality based on racial-economic segregation.3 Specifically, data showed that those who lived in Black and poor majority areas were less likely to receive care that was in accordance with various treatment guidelines while having worse overall survival outcomes. Regarding the next steps, Waheed described his intentions of sharing his findings with policymakers who may create legislature intended to mitigate the disparities observed in the analysis. References 1. Shannon AB, Mehta RJ, Mok SR, et al. Pathologic response to neoadjuvant immunotherapy in DNA mismatch repair protein-deficient gastroesophageal cancers. Presented at the Society of Surgical Oncology 2024 Annual Meeting; March 20-23, 2024; Atlanta, GA. Abstract 94. 2. Dineen S. Optimal tumor burden for CRS/HIPEC in colorectal cancer. Presented at the Society of Surgical Oncology 2024 Annual Meeting; March 20-23, 2024; Atlanta, GA. 3. Waheed MT, Sullivan KM, Haye S, et al. Impact of racialized residential segregation on guideline concordant cancer care and survival. Presented at the Society of Surgical Oncology (SSO) 2024 Annual Meeting; March 20 – 23, 2024; Atlanta, GA; abstract E126.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZR865. CME/MOC credit will be available until February 14, 2025.PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Biomarker Testing and Pathologic Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerKurt A. Schalper, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agenus Inc.; AstraZeneca; Bristol Myers Squibb; CDR-Life Inc.; Clinica Alemana de Santiago; EMD Serono Inc.; F.Hoffmann-La Roche; Genmab A/S; Indaptus Therapeutics; Janssen Pharmaceuticals, Inc.; Merck Sharpe & Dohme; Moderna, Inc.; Molecular Templates, Inc.; OnCusp Therapeutics; Parthenon/Incendia Therapeutics; Repertoire Therapeutics; Sanofi; Sensei Biotherapeutics; Shattuck Labs, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Akoya Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; F. Hoffmann-La Roche; Lilly; Merck Sharpe & Dohme; Ribon Therapeutics; Surface Oncology; Takeda Pharmaceutical Company Limited; and Tesaro Inc./GSK.Speakers Bureau participant with Bristol Myers Squibb; Fluidigm Corporation; Genmab A/S; Merck & Co., Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerVamsidhar Velcheti, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Galvanize Therapeutics, Inc.; GSK; Merck & Co., Inc.; Novocure; TAIHO ONCOLOGY, INC.; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZR865. CME/MOC credit will be available until February 14, 2025.PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Biomarker Testing and Pathologic Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerKurt A. Schalper, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agenus Inc.; AstraZeneca; Bristol Myers Squibb; CDR-Life Inc.; Clinica Alemana de Santiago; EMD Serono Inc.; F.Hoffmann-La Roche; Genmab A/S; Indaptus Therapeutics; Janssen Pharmaceuticals, Inc.; Merck Sharpe & Dohme; Moderna, Inc.; Molecular Templates, Inc.; OnCusp Therapeutics; Parthenon/Incendia Therapeutics; Repertoire Therapeutics; Sanofi; Sensei Biotherapeutics; Shattuck Labs, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Akoya Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; F. Hoffmann-La Roche; Lilly; Merck Sharpe & Dohme; Ribon Therapeutics; Surface Oncology; Takeda Pharmaceutical Company Limited; and Tesaro Inc./GSK.Speakers Bureau participant with Bristol Myers Squibb; Fluidigm Corporation; Genmab A/S; Merck & Co., Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerVamsidhar Velcheti, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Galvanize Therapeutics, Inc.; GSK; Merck & Co., Inc.; Novocure; TAIHO ONCOLOGY, INC.; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZR865. CME/MOC credit will be available until February 14, 2025.PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Biomarker Testing and Pathologic Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerKurt A. Schalper, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agenus Inc.; AstraZeneca; Bristol Myers Squibb; CDR-Life Inc.; Clinica Alemana de Santiago; EMD Serono Inc.; F.Hoffmann-La Roche; Genmab A/S; Indaptus Therapeutics; Janssen Pharmaceuticals, Inc.; Merck Sharpe & Dohme; Moderna, Inc.; Molecular Templates, Inc.; OnCusp Therapeutics; Parthenon/Incendia Therapeutics; Repertoire Therapeutics; Sanofi; Sensei Biotherapeutics; Shattuck Labs, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Akoya Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; F. Hoffmann-La Roche; Lilly; Merck Sharpe & Dohme; Ribon Therapeutics; Surface Oncology; Takeda Pharmaceutical Company Limited; and Tesaro Inc./GSK.Speakers Bureau participant with Bristol Myers Squibb; Fluidigm Corporation; Genmab A/S; Merck & Co., Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerVamsidhar Velcheti, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Galvanize Therapeutics, Inc.; GSK; Merck & Co., Inc.; Novocure; TAIHO ONCOLOGY, INC.; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZR865. CME/MOC credit will be available until February 14, 2025.PATHway to Decoding the Impact of Cancer Immunotherapy: Latest Advances in Biomarker Testing and Pathologic Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerKurt A. Schalper, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agenus Inc.; AstraZeneca; Bristol Myers Squibb; CDR-Life Inc.; Clinica Alemana de Santiago; EMD Serono Inc.; F.Hoffmann-La Roche; Genmab A/S; Indaptus Therapeutics; Janssen Pharmaceuticals, Inc.; Merck Sharpe & Dohme; Moderna, Inc.; Molecular Templates, Inc.; OnCusp Therapeutics; Parthenon/Incendia Therapeutics; Repertoire Therapeutics; Sanofi; Sensei Biotherapeutics; Shattuck Labs, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Akoya Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; F. Hoffmann-La Roche; Lilly; Merck Sharpe & Dohme; Ribon Therapeutics; Surface Oncology; Takeda Pharmaceutical Company Limited; and Tesaro Inc./GSK.Speakers Bureau participant with Bristol Myers Squibb; Fluidigm Corporation; Genmab A/S; Merck & Co., Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerVamsidhar Velcheti, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Galvanize Therapeutics, Inc.; GSK; Merck & Co., Inc.; Novocure; TAIHO ONCOLOGY, INC.; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
In this episode of SurgOnc Today®, Brian E. Kadera, MD, Ben Hinrichs, MD, and Konstantinos Chouliaras, MD, focus on the diagnosis and work-up of fatty tumors in the extremity and the retroperitoneum. They highlight the imaging features, the utility of biopsy and specifically, MDM2 fluorescence in-situ hybridization. They also review the pitfalls of gross and microscopic margin assessment.
R2P Sports Residency Research Article Review by Dr. Seth Hawks, DPT.
In this episode, we review the high-yield topic of Pathologic Gambling from the Psychiatry section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
Nick and Kevin discuss this very unique experience.
The Instruction Booklet - AYCH Xtra's monthly video game history show - is now on the main stage! Join Jeremy (co-host of Caging Greatness) & PhD student Michael as they explore the history of gaming! This month, the Instructors will explore what exactly makes a video game scary, from examining a game's environment, imposing limitations on the game's controls, and even blurring the line between what's real & what's imaginary for the player. Get ready to get informed and get spooky in this Halloween themed edition of The Instruction Booklet! ----------------------------------- Links for subjects in the show: - MyHouse.wad: https://www.youtube.com/watch?v=5wAo54DHDY0 - Signalis: https://store.steampowered.com/app/1262350/SIGNALIS/ - Dead Space: https://store.steampowered.com/app/1693980/Dead_Space/ - Control: https://www.remedygames.com/games/control/ - Pathologic: https://store.steampowered.com/app/384110/Pathologic_Classic_HD/ ----------------------------------- Follow the Hosts! Jeremy - Instagram: www.instagram.com/pressartf4/ - Twitch: twitch.tv/backwardshero Michael - Twitter: twitter.com/MackerelPrawns ----------------------------------- Follow the Show's Socials! - Twitter: twitter.com/Instruction_Bk - Facebook: www.facebook.com/InstructionBooklet
Kole, David, and Dennis talk about Baldur's Gate III, Pathologic 2, Swarm, and much more! The Grind: Dennis: Baldur's Gate III. Disco Elysium. Kole: Baldur's Gate III. Pathologic 2. Swarm. David: Starfield. The Multiplayer: Let's talk game rental memories. The End Boss: All about the Xbox Leak. Mortal Kombat's Switch port is a disaster. A discussion of “Press Any Key” splash screens.
CardioNerds co-founder Dr. Dan Ambinder joins CardioNerds join Dr. Pooja Prasad, Dr. Khoa Nguyen and expert Dr. Abigail Khan (Assistant Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine) from Oregon Health & Science University and discuss a case of mechanical valve thrombosis. Audio editing by CardioNerds Academy Intern, student doctor Adriana Mares. A 23-year-old pregnant woman with a mechanical aortic valve presented to the maternal cardiac clinic for a follow-up visit. On physical exam, a loud grade three crescendo-decrescendo murmur was audible and transthoracic echocardiography revealed severely elevated gradients across the aortic valve. Fluoroscopy confirmed an immobile leaflet disk. Thrombolysis was successfully performed using a low dose ultra-slow infusion of thrombolytic therapy, leading to normal valve function eight days later. Treatment options for mechanical aortic valve thrombosis include slow-infusion, low-dose thrombolytic therapy or emergency surgery. In addition to discussing diagnosis and management of mechanical valve thrombosis, we highlight the importance of preventing valve thrombosis during the hypercoagulable state of pregnancy with careful pre-conception counseling and a detailed anticoagulation plan. See this case published in European Heart Journal - Case Reports. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - mechanical valve thrombosis The hypercoagulable state of pregnancy presents a risk for women with mechanical heart valves with contemporary data estimating the rate of valve thrombosis during pregnancy at around 5%. Thrombolytic therapy is a (relatively) safe alternative to surgery and should be considered first line for treatment of prosthetic valve thrombosis in all patients, especially in pregnant women. Pre-conception counselling and meticulous anticoagulation management for patients with mechanical heart valves are key aspects of their care. The evaluation for prosthetic valve thrombosis in pregnant persons requires a review of anti-coagulation history and careful choice of diagnostic testing to confirm the diagnosis and minimize risks to the parent and the baby. Multi-disciplinary care with close collaboration between cardiology and obstetrics is critical when caring for pregnant persons with cardiac disease. Show Notes - mechanical valve thrombosis How can we counsel and inform women with heart disease who are contemplating pregnancy? Use the Modified World Health Organization classification of maternal cardiovascular risk to counsel patients on their maternal cardiac event rate and recommended follow-up visits and location of delivery (local or expert care) if pregnancy is pursued. To learn about normal pregnancy cardiovascular physiology and pregnancy risk stratification in persons with cardiovascular disease, enjoy CardioNerds Episode #111. Cardio-Obstetrics: Normal Pregnancy Physiology with Dr. Garima Sharma. Adapted from the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy What is the differential diagnosis for a new murmur in a pregnant person who has undergone heart valve replacement? Normal physiology - elevated flow from hyperdynamic state and/or expansion of blood volume in pregnancy. Pathologic - increased left ventricular outflow tract flow from turbulence of flow due to pannus ingrowth, new paravalvular leak, or obstructive mechanical disk motion from vegetation or thrombus. What are diagnostic modalities for the evaluation of suspected prosthetic valve thrombosis? The 2020 ACC/AHA guidelines gave a class I recommendation for evaluation of susp...
Nate, Sebastian, Jordan, and Brock gather to discuss PATHOLOGIC 2, the "open-world horror RPG" developed by Ice-Pick Lodge and released in 2019. We discuss brutality both thematic and mechanical, folk horror, and starving to death on the steppe. Nate becomes an evangelist for a game he wasn't sure he'd like, Brock gets to know his co-workers in the most awkward way, and Sebastian is stymied by the unforgiving hands of time.
THIS WEEK: Peter fires up the Batmobile while dealing with Scarecrow's fear toxin in Gotham City with David Buckley's work in Batman: Arkham Knight and Joe struggles through 12 days in a plague-infested Russian town in Pathologic.
Receiving information or research that contradicts your beliefs can be discomforting. Place that evidence into the conversation of a controversial subject and the environment is ripe for elevated conflict. What is happening here in the United States? Evidence suggests known risks from drugs may induce violence—contributing to the problem, not solving the problem.If you are in a crisis or think you have an emergency, call your doctor or 911. If you're considering suicide, call 1-800-273-TALK to speak with a skilled trained counselor.RADICALLY GENUINE PODCASTRadically Genuine Podcast Website Twitter: Roger K. McFillin, Psy.D., ABPPInstagram @radgenpodTikTok @radgenpodRadGenPodcast@gmail.comADDITIONAL RESOURCES1:00 - Radically Genuine Podcast | 39. Mass shootings2:00 - Dr. Roger McFillin on Twitter: "It's a bad idea to ignore how many school shooters were on at least 1 psychiatric drug. To ignore the black box warning on antidepressants. To ignore the FDA's adverse event reporting system14:30 - Peter Breggin: Suicidality, violence and mania caused by SSRIs: A review and analysis17:30 - Treatment Emergent Violence To Self And Others; A Literature Review of Neuropsychiatric Adverse Reactions For Antidepressant And Neuroleptic Psychiatric Drugs And General Medications20:00 - Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers24:30 - Psychiatry.org - What is Mental Illness?40:00 - Mirror mirror on the ward, who's the most narcissistic of them all? Pathologic personality traits in health care41:45 - What Is Cognitive Dissonance? Definition and Examples56:00 - SAGE updates COVID-19 vaccination guidance58:00 - Meanings and origin of ‘Judas sheep' and ‘Judas goat' | word histories1:01:30 - Dr. McFillin on Twitter: Why has American health care become pharmaceuticals & psych drugs are pushed on kids? American Academy of Pediatrics. Here is a list of some of their corporate donors
Go online to PeerView.com/GNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the continued expansion of the cancer immunotherapy arsenal, reliable biomarkers to identify patients most likely to benefit from specific agents or combinations have become crucial. Predictive biomarkers such as measurement of PD-L1 expression and assessment of MSI/MMR or TMB status have an established role in some tumor types and settings, but a number of challenges related to testing and interpretation of results persist, and significant improvements are needed. There is also a need for ways to assess response to immunotherapies as they transition to early-stage, curative-intent settings as part of perioperative multimodal management of solid malignancies. Recently, pathologic response assessment has emerged as a potential new gold standard for measurement of impact of neoadjuvant immunotherapy. However, there has been limited guidance on how to define pathologic response, process and evaluate resected specimens, and report and apply assessment results in the settings of clinical trials and practice. This PeerView educational activity, based on a recent live symposium, focuses on current and emerging immunotherapy biomarkers, the rationale for and practicalities of biomarker testing as a guide for immunotherapy selection for different solid tumors, and the nuances of pathologic response assessment after neoadjuvant immunotherapy. Additionally, practical guidance is provided to help multidisciplinary coordination of care based on biomarker testing and pathologic response assessment so that more patients receive personalized immunotherapy and experience improved outcomes. Upon completion of this activity, participants should be better able to: Explain the evidence and rationale for the role of biomarkers to predict and assess response to cancer immunotherapy in metastatic and resectable solid malignancies; Conduct cancer immunotherapy biomarker testing and pathologic response assessment congruent with the latest evidence, requirements, and recommendations; and Personalize cancer immunotherapy treatment and response assessment by collaborating with multidisciplinary care team members to optimally select and interpret biomarkers.
Go online to PeerView.com/GNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the continued expansion of the cancer immunotherapy arsenal, reliable biomarkers to identify patients most likely to benefit from specific agents or combinations have become crucial. Predictive biomarkers such as measurement of PD-L1 expression and assessment of MSI/MMR or TMB status have an established role in some tumor types and settings, but a number of challenges related to testing and interpretation of results persist, and significant improvements are needed. There is also a need for ways to assess response to immunotherapies as they transition to early-stage, curative-intent settings as part of perioperative multimodal management of solid malignancies. Recently, pathologic response assessment has emerged as a potential new gold standard for measurement of impact of neoadjuvant immunotherapy. However, there has been limited guidance on how to define pathologic response, process and evaluate resected specimens, and report and apply assessment results in the settings of clinical trials and practice. This PeerView educational activity, based on a recent live symposium, focuses on current and emerging immunotherapy biomarkers, the rationale for and practicalities of biomarker testing as a guide for immunotherapy selection for different solid tumors, and the nuances of pathologic response assessment after neoadjuvant immunotherapy. Additionally, practical guidance is provided to help multidisciplinary coordination of care based on biomarker testing and pathologic response assessment so that more patients receive personalized immunotherapy and experience improved outcomes. Upon completion of this activity, participants should be better able to: Explain the evidence and rationale for the role of biomarkers to predict and assess response to cancer immunotherapy in metastatic and resectable solid malignancies; Conduct cancer immunotherapy biomarker testing and pathologic response assessment congruent with the latest evidence, requirements, and recommendations; and Personalize cancer immunotherapy treatment and response assessment by collaborating with multidisciplinary care team members to optimally select and interpret biomarkers.
Interview with Dian Wang, MD, author of Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. Hosted by Jack West, MD. Related Content: Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy
Do you ever wonder why some people have the ability to bounce from success to success in business and life, without faltering? On this episode of The Uncaged Clinician, Kevin and Hannah DeGroot will talk to you about how to build the proper success mindset as an Uncaged clinician so you can thrive in business. Hannah is a licensed clinical mental health counselor (CO), addictions specialist, and trained Enneagram coach. She specializes in helping people better understand themselves and develop healthy strategies for managing stress in their professional and personal lives. Hannah is the Uncaged Clinician Professional Development Coach and is passionate about helping entrepreneurs get out of their own way to reach their full potential. They will touch on topics such as: Mindset for business owners 101: The cheerleaders versus the challengers. Pathologic-based approaches to counseling. How personality types play into the kind of mindsets we adopt and live by. Changing the lens of how you view things so you can move forward successfully. Understanding StrengthsFinder and the working genius model. The Enneagram and why it's important to know your personality type. Where to start to invest in your mindset and personal development. Reach to out to Hannah DeGroot: https://methodandmind.clientsecure.me/ Additional Resources: When you are ready…Here are ways that we can help you to grow your practice: If you're ready to join our community of Uncaged Healthcare Professionals and become UNCAGED in 2023! Fill out the application to JOIN our Pathway Program! PATHWAY https://api.leadconnectorhq.com/widget/form/Y6ABODFCd53KLdo9SPfy Join the UNCAGED Clinician Facebook community. YES, you have a community that you can immediately plug into where you can learn to grow a six-figure practice: https://facebook.com/groups/113576786080229
Dr. Marco Quarta, CEO and Co-founder of Rubedo Life Sciences, joins Chris on today's episode to discuss his company's strategy of targeting pathologic cells to develop therapeutics for chronic degenerative conditions. The conversation covers the evolving definition of senescence and the challenges of identifying and classifying pathologic cells, which vary across different tissues and indications. Marco also announces the upcoming Senotherapeutic Summit in November, which will bring together stakeholders from different fields to advance therapeutic research. Marco and Chris also review Rubedo Life Sciences' clinical development approach: targeting the aging process with the goal of helping healthy stem and immune cells to repair. They then go on to discuss the funding and work required for the selection and nomination of a lead candidate for a project, the importance of having access to primary clinical samples to test efficacy, and the subsequent steps of the grant awarding process. The conversation then turns to the value of having multiple programs running simultaneously. Tune in today to learn more about the ‘sneaky' process of senescence that accelerates aging, the toxicity of these rare cells and the development of small molecules that can target them, the complexities of developing new therapies, and the value of having a robust pipeline of programs to advance therapeutic R&D.The Finer Details:Defining pathological cells and their role in chronic degenerative conditionsIdentifying, classifying, and targeting senescent cellsThe need for a focused effort in identifying specific targets for therapeuticsThe evolution of the definition of senescence and the existence of multiple types of senescent cellsThe Senotherapeutic Summit in November and its goal of advancing the field of therapeuticsRunning multiple programs simultaneouslyThe upcoming event in Saudi Arabia aimed at accelerating and promoting healthy longevity.Quotes:"These are aberrant cells, dysfunctional cells, and maladaptive cells that are contributing to shift the microenvironment and leading to progression of chronic degenerative conditions, driving chronic inflammation, fibrosis, stem cell depletion, and cancer.""There are no universal pathologic cells across all tissues or indications. So it really depends on your question and finding targets associated with those that you can really go after in a drug discovery pipeline to generate therapeutics." "We are hoping to push forward the conversation about what senescent cells are, how we can classify them, and how we can move forward with targeting these cells.""We are testing back to back multiple indications including for example, chronic age related atopic dermatitis and others.""And it's a very important event that we'll have major stakeholders from high level government officials and scientists and innovators business leaders and really the idea of promoting a healthy longevity and how can we accelerate this."Links: Email questions, comments, and feedback to podcast@bioagelabs.comTranslating Aging on Twitter: @bioagepodcastBIOAGE Labs Website BIOAGELabs.comBIOAGE Labs Twitter @bioagelabsBIOAGE Labs LinkedInRubedo...
Full article: https://www.ajronline.org/doi/10.2214/AJR.22.28385 Locoregional therapies for hepatocellular carcinoma perform differently when compared by rates of complete pathologic necrosis of lesions. Juliet Alla, MD discusses a new AJR study that demonstrates improved rates of complete pathologic necrosis for patients with HCC who underwent thermal ablation and TARE therapies, when compared to those who received TACE. Special guest Dr. Zachary Berman, an interventional radiologist who specializes in locoregional therapies for hepatocellular carcinoma, joins to discuss the implications for clinical practice.
Audible Bleeding editor Adam Johnson (@Adam_mdmph) is joined by MD/Ph.D. student Rahul Ghosh (@ghoshrx) and JVS Assistant Editor Dr. Paul Dimuzio (@pdimuziomd) to discuss the second highlighted article for January in the JVS family of journals. Dr. David Gordon and Dr. David Williams, the authors of the following paper, join them: “Pathologic characteristics of human venous in-stent stenosis and stent occlusion” by Williams et al. Show Guests: Dr. David Gordon (faculty page) is the Emeritus Professor of Pathology at the University of Michigan, and serves as the Director for Cardiovascular Pathology. He has also had much experience with both human cardiovascular and associated animal model research. Dr. David Williams (faculty page) is the Kyung J. Cho Collegiate Professor of Radiology in the Division of Vascular and Interventional Radiology at the University of Michigan Medical School Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation.
Episode at a Glance On this episode of Melody and Friends, I sit down with my friend Sandra Brown to talk about pathology and more specifically dangerous, pathologic partners in relationships. Sandra explains her history in studying pathology and why it is such an important field of study when it comes to abuse in relationships. She tells us what pathology is, how to identify the signs of pathologic partners, and what we can do to help women heal from these extremely traumatic situations. She also walks through her development of Pathological Love Relationship training for other professionals, and how she has developed survivor-based support services for women who experienced psychopathic partners. Sandra then talks about personality disorders, from Narcissism to Anti-Social Behavior to Psychopathy, and how each of these types can cause significant damage to a woman emotionally. However, she also provides warning signs to look out for and multiple resources to begin the process of healing from these potent forms of abuse. Who is Sandra Brown? Sandra L. Brown, MA, has spent over 30 years working in the psychology field related to psychopathology. Her earlier years were spent developing a dual-focused treatment center for persons with personality disorders who also had trauma disorders. During this time, she also began working, in individual and group sessions, with the partners and children of those with personality disorders. She eventually established one of the country's first prototype long-term residential treatment centers for women with Multiple Personality Disorder/Dissociative Identity Disorder. Sandra accomplished this while also providing treatment in a women's inpatient hospital trauma program. Things We Talk About In This Episode: What is pathology and why can it often impact victims in a relationship so much more deeply then other forms of abuse? Why isn't pathology as well studied or understood compared to things like depression or anxiety? What methods of treatment are available for victims? What should they be looking out for in relationships to spot warning signs of this behavior? What are personality disorders? How can this affect partners in a relationship? Resources: Our listeners can learn more about Sandra's Training, speaking engagements, and get in contact with Sandra by visiting her website: www.sandralbrownma.com You can also find all of her books, including How To Spot A Dangerous Man, by visiting her Amazon Page here: www.amazon.com/stores/Sandra-L.-Brown Thank you so much for listening to this episode of Melody and Friends! If you haven't already please take the time to leave us a rating and review on our iTunes page as it helps us get more great episodes like this to you!
As the owner of Cat Parker Photography, I could not be any more thrilled at where my career was going. Photographing my favorite musicians such as George Lynch, Dokken, Great White, Slaughter, Rick Springfield, Billy Idol, and many more, I felt on top of the world. I also managed a corporate construction company as an Office & Restoration Project Manager, traveled, and as a single mom, took care of two young adult children.During the pandemic, I was mandated to get the covid vaccine. I did my due diligence and researched whatever information I could find and asked my GP if it was safe to take. I doctor stated that it was safe & effective. I assumed I had nothing to worry about and was not against the vaccine and believed I was doing the right thing like so many others. I received the Johnson & Johnson shot on 04/04/2021. Within a month I began experiencing chronic insomnia & fatigue. I went to see several doctors that dismissed the fatigue & insomnia as menopause and overworking. They even gave me two iron infusions to combat the fatigue, but nothing helped. On 11/09/2021 again I was mandated to get the booster to travel for work. This time within 2 weeks, the side effects began with my hair falling out. After that, it seemed that there was no stopping this shot from attacking my neurological system and body.During this time, I began to get sicker and was terminated from my job because of my condition. By this time, I had lost everything. I had lost my job, my health, and my financial security. Since taking the Pfizer booster I have been diagnosed with narcolepsy, sleep apnea, adrenal insufficiency, pseudoparkinsonism, dysautonomia, Epstein Barr Virus, Pathologic hypersomnia, Idiopathic CNS Hypersomnia, Chronic Vasomotor Rhinitis, Vertigo, and Chronic Tinnitus. I have chronic bleeding & blood clots, imbalance, memory loss, brain fog, kidney issues, swelling, rashes & chronic pain.Even going through all of this, I found the courage to come forward and founded a Facebook vaccine injured support group as well as an uncensored support group on TrialSite News to help those in need just like I. I have volunteered with React19 & Operation Truth as well to help those organizations get the support they need. I could not simply sit by and watch others suffer and be ignored, the way I was. The gaslighting, cruelty, and being invisible to the rest of the world. I will not idly stand by and will fight for all of us. I want to make an impact on the lives that have been affected by the covid 19 shots. I want to make a change and a change is needed so we never have to go through this travesty again.Connect with Cat Parkerhttps://www.facebook.com/groups/3217567388501402https://poplme.co/catparkerphotohttps://www.tiktok.com/@catparkerphotohttps://www.trialsitenews.com/groups/4/covid-vaccine-injury-support-groupSupport the showThanks for listening and make sure to rate us on the podcast platform you are listening to!
New series! We are tackling Dark Souls: The Masque of Vindication, by Michael A. Stackpole. The book follows the adventures of an Undead named Ferranos who is traveling through the land of Trafaram on a quest to figure out why he has been awoken from death. Along the way he meets friends, enemies, bonfires and more! Show Notes 1:25 - Opening back and forth. Recap of Kevin's new podcast he is co-hosting with HotCyder called Bullet Time. 2:44 - Topic intro, what is Dark Souls? (Lol.) 6:54 - Phil gives background on the author of the book, Michael Stackpole. 10:08 - Beginning of the book section. 46:10 - Kitty cat arrival. 1:16:15 - Whaddya Playin? Games discussed: Strange Horticulture, Warhammer 40k Chaos Gate Demon Hunters, Titanfall 2, Pathologic 2, Faith: The Unholy Trilogy, Red Dead Redemption 2 Follow us on Twitter: https://twitter.com/pixellitpod Our website: https://www.pixellitpod.com Our discord: https://discord.gg/NdwmVEwFbQ Join our Steam Group: https://steamcommunity.com/groups/pixellitpod PixelLit is the video game-literary nerd's dream come true. It's a podcast where we read and discuss video game novelizations, and the games they're based on. This is a podcast for the former kid who read their instruction booklets cover to cover. For the gamer who listens to every audio log in Bioshock. The PixelLit Podcast! Because the only thing better than playing a video game is reading about it
A full cast today with Rico, James, Nando, Germayn and David! We talk about what scared us when we were young, telling scary stories of our encounters, and this list of 15 Scariest Games of All time! Do we agree? Do you agree with this list? Find out on this episode of the podcast. Plus let us know at UnsungGamers.com what your scariest game of all time is. Scariest Games of All Time, per howstuffworks.com 15. Resident Evil 14. Dead Rising 13. Clock Tower 12. Bloodborne 11. Five Nights at Freddy's 10. Slender 9. Condemned: Criminal Origins 8. Resident Evil 7 7. S.T.A.L.K.E.R.: Shadow of Chernobyl 6.Pathologic 2 5.Silent Hill 2 4. Dead Space 3. Alien: Isolation 2. Amnesia: The Dark Descent 1. Outlast --- Support this podcast: https://anchor.fm/unsung-gamers/support
© 2020-2025 Ivy Podcast Discovery LLC
